Abstract
The disproportionate cost of treating asthmatic patients who do not respond to conventional anti-inflammatory therapies makes delineation of the mechanism for glucocorticoid resistance an important field of asthma research. Unbiased cluster analysis indicates that asthma is a syndrome with a number of distinct phenotypes and 5-10% of asthmatics fall into this category of relative glucocorticoid insensitivity. This sub-population is itself divided into smaller subsets which have different underlying mechanisms for this relative glucocorticoid resistance ranging from an inherited genetic basis to specific kinase signalling pathways triggered by exposure to environmental stressors such as cigarette smoking or infection. Whilst the underlying mechanisms are becoming better understood there remains a lack of effective novel therapies. However it is clear that relative glucocorticoid insensitive patients who are smokers should be encouraged to quit, thereby reducing their oxidant load. Novel treatments will consist of either developing new anti-inflammatory treatments targeting pathways aberrantly activated in these patients or of suppressing signalling pathways that attenuate glucocorticoid receptor function and thereby restoring glucocorticoid sensitivity. It will be important to uncover non-invasive biomarkers for aberrant pathway activation and for discerning which components of glucocorticoid receptor activation are abnormal if future treatments are to be tailored to address these specific issues. Conventional combination therapies will continue to be used in the near future but additional add-on treatments using drugs directed against aberrantly expressed inflammatory pathways or mediators along with an inhaledglucocorticoid are likely to prove the most effective new therapies in the future.
Keywords: Severe asthma, glucocorticoid receptor, MAPK, oxidative stress, eosinophils, hypersecretion, epithelium, cytoplasm, phosphorylation, glycogen synthase, nitric oxide, dexamethasone, hydrogen peroxide, HNF2, GRIP-1, S-nitrosylation
Current Pharmaceutical Design
Title: Steroid Resistance in Severe Asthma: Current Mechanisms and Future Treatment
Volume: 17 Issue: 7
Author(s): A Durham, IM Adcock and O Tliba
Affiliation:
Keywords: Severe asthma, glucocorticoid receptor, MAPK, oxidative stress, eosinophils, hypersecretion, epithelium, cytoplasm, phosphorylation, glycogen synthase, nitric oxide, dexamethasone, hydrogen peroxide, HNF2, GRIP-1, S-nitrosylation
Abstract: The disproportionate cost of treating asthmatic patients who do not respond to conventional anti-inflammatory therapies makes delineation of the mechanism for glucocorticoid resistance an important field of asthma research. Unbiased cluster analysis indicates that asthma is a syndrome with a number of distinct phenotypes and 5-10% of asthmatics fall into this category of relative glucocorticoid insensitivity. This sub-population is itself divided into smaller subsets which have different underlying mechanisms for this relative glucocorticoid resistance ranging from an inherited genetic basis to specific kinase signalling pathways triggered by exposure to environmental stressors such as cigarette smoking or infection. Whilst the underlying mechanisms are becoming better understood there remains a lack of effective novel therapies. However it is clear that relative glucocorticoid insensitive patients who are smokers should be encouraged to quit, thereby reducing their oxidant load. Novel treatments will consist of either developing new anti-inflammatory treatments targeting pathways aberrantly activated in these patients or of suppressing signalling pathways that attenuate glucocorticoid receptor function and thereby restoring glucocorticoid sensitivity. It will be important to uncover non-invasive biomarkers for aberrant pathway activation and for discerning which components of glucocorticoid receptor activation are abnormal if future treatments are to be tailored to address these specific issues. Conventional combination therapies will continue to be used in the near future but additional add-on treatments using drugs directed against aberrantly expressed inflammatory pathways or mediators along with an inhaledglucocorticoid are likely to prove the most effective new therapies in the future.
Export Options
About this article
Cite this article as:
Durham A, Adcock IM and Tliba O, Steroid Resistance in Severe Asthma: Current Mechanisms and Future Treatment, Current Pharmaceutical Design 2011; 17 (7) . https://dx.doi.org/10.2174/138161211795428984
DOI https://dx.doi.org/10.2174/138161211795428984 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Production of nanosuspensions as a tool to improve drug bioavailability: focus on topical delivery
Current Pharmaceutical Design Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development
Current Medicinal Chemistry Hypersensitivity Reactions from Excipients in Systemic Glucocorticoid Formulations
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry COVID-19-associated Coagulopathy and Thromboembolism: Determination of Their Patterns and Risk Factors as Predictors of Mortality Among Severe COVID-19 Patients
Current Vascular Pharmacology Prevention of Respiratory Syncytial Virus: A Review
Current Respiratory Medicine Reviews Sleep and COPD
Current Respiratory Medicine Reviews Cow’s Milk Allergenicity
Endocrine, Metabolic & Immune Disorders - Drug Targets Immunotherapeutic Targeting of Allergic Disease
Inflammation & Allergy - Drug Targets (Discontinued) Microbiology of the Human Intestinal Tract and Approaches for Its Dietary Modulation
Current Pharmaceutical Design CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Mini-Reviews in Medicinal Chemistry A Review of the Chemical and Pharmacological Aspects of the Genus Marrubium
Current Pharmaceutical Design A Novel Nanoformulation of Ellagic Acid is Promising in Restoring Oxidative Homeostasis in Rat Brains with Alzheimer’s Disease
Current Drug Metabolism Overview of the Primary Structure, Tissue-Distribution, and Functions of Tachykinins and their Receptors
Current Drug Targets Synthesis and Biological Activity of Prostaglandin Analogs Containing Heteroatoms in the Cyclopentane Ring
Current Organic Chemistry Influenza Antiviral Therapeutics
Recent Patents on Anti-Infective Drug Discovery Interventions to Support Diabetes Self-Management: The Key Role of the Patient in Diabetes Care
Current Diabetes Reviews Proteostasis, an Emerging Therapeutic Paradigm for Managing Inflammatory Airway Stress Disease
Current Molecular Medicine Inhaled Biologics: From Preclinical to Product Approval
Current Pharmaceutical Design Electronic Noses in Medical Diagnostics
Current Medicinal Chemistry Melanin-Concentrating Hormone Receptor 1 Antagonists: A New Perspective for the Pharmacologic Treatment of Obesity
Current Medicinal Chemistry